Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis

NCT05828225 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Myasthenia Gravis

Interventions

DRUG: CD19 CAR-T cells injection

Sponsor

Zhejiang University